Algethami et al., J Nanomater Mol Nanotechnol 2017, 6:4
DOI: 10.4172/2324-8777.1000222
Journal of Nanomaterials &
Molecular Nanotechnology
Research Article
Bismuth Sulfide Nanoparticles
as a Complement to Traditional
Iodinated Contrast Agents
at Various X-Ray Computed
Tomography Tube Potentials
Merfat Algethami1, Anton Blencowe2,3, Bryce Feltis4 and Moshi
Geso1*
Abstract
Background: Investigation of the contrast enhancement effects on
the CT images of the conventional iodinated contrast media (CM)
or bismuth sulfide nanoparticles (Bi2S3 NPs) with increasing x-ray
tube potentials.
Materials and methods: A phantom was filled with iodinated CM or
Bi2S3 NP solutions at concentrations ranging from 0 to 65 mM and
the phantom was scanned with a CT scanner using tube potentials
of 80, 100, 120 and 140 kVp at a fixed current of 200 mA. The
CT contrast enhancement and contrast-to-noise ratios (CNR) of all
scanned images were calculated.
Results: This study demonstrated that greater image contrast
was observed with Bi2S3 NPs compared to the iodinated CM at
all concentrations and energies (80-140 kVp) tested. For example, at a concentration of 65 mM and tube potential of 140
kVp, a CNR enhancement of three to four times was observed
for Bi2S3 NPs compared to iodinated CM. Even at a conventional
tube potential of 80 KVp, one to two-fold increase in CNR was
noted for Bi2S3 NPs. Results are also demonstrated that CNR
increased with increasing concentration of Bi2S3 NPs at a fixed
tube potential.
Conclusion: These results highlight the effects of the different
physical densities and atomic numbers of the two elements (I
versus Bi), and their role in enhancing the probability of Compton
scattering (CS) and photoelectric effects (PEs). As tube potential
was increased, the CT numbers for both Bi2S3 NPs and iodinated
CM decreased, consistent with a decrease in the probability of
CS and PEs with increasing beam energy. However, the rate of
decrease for iodinated CM was larger than Bi2S3 NPs. A good
correlation was observed between the experimental results and
the theoretical spectra based on linear attenuation coefficients.
Keywords
Bi2S3; Nanoparticles; Contrast agent; Computed tomography;
Contrast medium
*Corresponding author: Moshi Geso, Discipline of Medical Radiations, School
of Health and Biomedical sciences, RMIT University, Melbourne, Victoria 3109,
Australia, Tel: +61399257991; E-mail: moshi.geso@rmit.edu.au
Received: May 02, 2017 Accepted: June 02, 2017 Published: June 07, 2017
International Publisher of Science,
Technology and Medicine
a SciTechnol journal
Introduction
Medical imaging modalities, such as magnetic resonance imaging
(MRI), computed tomography (CT), positron emission topography
(PET) and single photon emission computed tomography (SPECT)
are commonly used to diagnose and guide treatment. X-ray CT is the
most frequently employed, owing to its availability, low cost, deep tissue penetration, and ability to provide high-resolution 3D images of
anatomical structures in a short timeframe. However, while CT can
generate highly detailed tomographic images of electron-dense materials, its ability to differentiate subtle changes between soft tissues is
limited. This is because most soft tissues have very similar CT numbers, ranging from -100 to 100 Hounsfield units (HU), which are a
measure of X-ray attenuation in CT images [1,2]. Consequently, CT
contrast agents with high X-ray attenuation coefficients are necessary
for contrast enhancement in regions of interest [3].
The interaction between the incident radiation and the contrast
media results in significant contrast improvements for diagnostic imaging of soft tissues. Contrast agents based on iodinated compounds
have been used extensively in radiologic imaging since the 1920s [47]. Despite effective attenuation, versatile synthesis methods, high
solubility and body tissue tolerance, iodinated contrast agents suffer
from several drawbacks, especially for certain groups of patients [4,810]. The main limitation of iodinated contrast agents is their short
circulation times (<10 min) resulting from renal clearance by the kidneys, and thus rapid CT image acquisition is required [11,12]. In addition, iodinated contrast agents have a non-specific bio-distribution
throughout the intravascular and extravascular spaces resulting in
poor contrast, especially in larger patients [4,13,14]. Generally, larger
doses of contrast agents are required to counteract their rapid renal
elimination, which can induce hypersensitivity reactions and can
have other serious adverse effects [15-17].
Recently, several strategies have been introduced to improve the
efficiency and reduce the toxicity of iodinated contrast agents. For example, polymeric and lipid nanoparticulate systems have been used
to encapsulate iodinated contrast agents [4,14,18,19]. However, these
approaches have had limited success due to the high concentrations
of iodinated contrast agents required for encapsulation and lengthy
purification methods [20]. Furthermore, targeted imaging with these
nanoparticulate systems still remains a major challenge due to the
difficulty in conjugating specifically targeted biological components
to these materials and the subsequently low payloads/concentrations
that are delivered to the target, resulting in low CT sensitivity [6,21].
In CT scans, the majority of photons used at the image receptor
are of high energy (>60 KeV). However, the atomic number (Z=53)
and K-edge value (33.2 KeV) of iodine means that its contrast is only
sensitive to low energy X-rays. This is due to the high absorption of
low-energy photons, which results in a beam-hardening artefact. In
other words, the low energy photons that are absorbed have less contribution in the CT diagnostic energy range. The result of this is that
iodine has its optimal effect only at low energy. Thus, higher atomic
number elements are more desirable to enhance the CT efficiency.
The development of various nanoscale metal-based contrast
agents has been proposed as a means to overcome the shortcomings
of traditional iodinated contrast agents [4,22]. In particular, nanoparticle (NP)-based contrast media deliver heavy atoms with greater bio-
All articles published in Journal of Nanomaterials & Molecular Nanotechnology are the property of SciTechnol, and is protected
by copyright laws. Copyright © 2017, SciTechnol, All Rights Reserved.
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
compatibility, higher contrast densities and longer circulation times
to targets more efficiently than conventional contrast agents [23].
These longer circulation times facilitate the imaging process and allow
better visualization of blood vessels and tumours. Recently, high density metals such as gold (Au) and bismuth (Bi) have been formulated
as nanoparticles and have been shown to have relatively long blood
circulation times compared to iodinated contrast agents.
Au NPs with diameters of 1.9 nm have been reported to have
circulation times of ~ 15 h in mice [24], whereas bismuth sulfide
(Bi2S3)-NPs (50 nm) have demonstrated that the circulation times of
140 min [12], both significant improvements on clinical iodinated
contrast agents (<10 min).
There have also been numerous advances in the preparation of Au
NPs as contrast agents for CT, with their size, shape and surface coating being tunable parameters [25-28]. However, the widespread use of
Au remains low due the high costs involved.
Bismuth is low toxic, cost effective alternatives to Au. Bismuthbased compounds have also been used for many years for the treatment of various conditions and diseases. For example, bismuth containing pharmaceuticals are used for the treatment of gastrointestinal
disorders [29-31], such as the eradication of Helicobacter pylori in
peptic ulcers [29,32-34], syphilis, tumours [35] and for reducing the
renal toxicity caused by cisplatin [36]. Bismuth-based NP contrast
agents for CT possess several advantages over conventional iodinated
and Au-based NP contrast agents as a result of their high atomic number (Z=53 (I); 79 (Au); 83 (Bi)), high X-ray attenuation [12,20,37,38],
low cost (~$ 0.02 g-1) [20,37,39], and low toxicity [12,40]. Bi2S3 is one
of the most promising NP contrast agents due to its high effective
nuclear charge (Zeff=76.2), physical density (ρm=6780 Kg.m-3), and
electron density (ρe=2.20×1029 e.m-3). This high density of free electrons increases the probability for Compton scattering, which is of
particular interest in X-ray-based imaging and radiotherapy [4].
Rabin et al. demonstrated that polyvinylpyrrolidone (PVP) coated
Bi2S3 NPs displayed a five-fold increase in CT signal enhancement at a
tube potential of ~50 KVp and a lower-cytotoxicity profile compared
to the iodine contrast agent Iopromide in liver hepatocyte (HepG2)
cells and similar cytotoxicity profiles were also reported in macrophage (U937) cells [12]. Cytotoxicity studies comparing Bi2S3 NPs
and Bi subsalicylate in these cell lines demonstrated higher cytocompatibility with the former. Kinsella et al. conjugated Bi2S3 NPs with
Lyp-1 cyclic peptides, a specific target for breast cancer in mice [41].
Following intravenous administration and CT scanning, the conjugated Bi2S3 NPs were found to produce clearer images and higher CT
numbers in the target tumours compared to non-targeted NPs [41].
In addition to diagnostic applications, there has been recent interest
in the use of Bi2S3 NPs as radiosensitisers for cancer therapy. In both
phantom [42] and cell studies [40], we have demonstrated that Bi2SNPs were superior to Au NP for radiation dose enhancement.
3
In this study, we aimed to validate our previous work and demonstrate that Bi2S3 NPs provide significant increases in X-ray attenuation rates at clinical tube potentials ranging from 80 to 140 KVp,
in comparison to conventional iodinated contrast agents. This work
highlights the potential of Bi2S3 NPs to provide higher contrast and
more detailed CT images.
Experimental
Materials and syntheses
Materials: Oleic acid (99.9%), oleyl amine (70%), octadecane
(99%), thioacetamide (99%) and bismuth neodecanoate were purVolume 6 • Issue 4 • 1000222
chased from Sigma Aldrich, United States. Poly (vinyl pyrrolidone)
(MW=8000) was purchased from Alfa Aesar, United States. Omnipaque™ (Iohexol; 350 mg/mL) was purchased from GE Healthcare,
United Kingdom. All chemicals were used without further purification unless otherwise stated. PVP coated Bi2S3 NPs with diameters of
5-15 nm were synthesized as reported previously [37,40].
Preparation of Bi2S3 NP solutions: Bi2S3 NPs (56.6 mg) were
suspended in Milli-Q water (2.2 mL) with sonication (100 W) for 10
min. The resulting stock solution was diluted with Milli-Q water to
obtain solutions with Bi concentrations ranging from 0 to 65 mM.
Preparation of iodine solutions: Clinical iodinated contrast media (Omnipaque 350 mgI.mL-1) was utilized for comparison in this
study. The Omnipaque stock was diluted with Milli-Q water to afford
solutions with iodine concentrations ranging from 0 to 65 mM.
Characterization
Dynamic light scattering (DLS) was conducted on a Malvern
Zetasizer Nano ZS 90, and was employed to determine the hydrodynamic diameter (Dh) of Bi2S3 NPs. Transmission electron microscopy
(TEM) was used to observe the morphology and size of the Bi2S3 NPs.
TEM images were acquired using a JEOL TEM 1010 with an accelerating voltage of 100 KeV. Samples were prepared by evaporating the
dilute solutions of NPs in isopropyl alcohol (IPA) onto strong carboncoated copper grids and air drying before TEM. X-ray powder diffraction (XRD) spectroscopy was carried out using an X-ray diffractometer (D8 ADVANCE, Bruker AXS) with a Cu-Ka radiation source.
CT scanning
CT images were acquired using a Light Speed™ VCT scanner
(single-slice) (GE Healthcare, Waukesha, WI, USA) at the Heidelberg
Repatriation Hospital, Australia. Samples were imaged in Perspex
phantoms positioned at the iso-center of the CT gentry. Phantoms
consisted of eight holes filled with Omnipaque and Bi2S3 NPs solutions (2 mL) at concentrations ranging from 0 to 65 mM (Figure 1).
The phantom consisted of five blocks in parallel to mimic 5 cm2 of
equivalent attenuation. CT imaging was initially conducted at a tube
potential of 80 kVp and current of 200 mA, with a slice thickness of
5 mm. Subsequently, CT scanning was repeated at tube potentials of
100, 120 and 140 KVp whilst keeping all other parameters constant.
The CT value, in Hounsfield Units (HU) for each sample and tube
potential was determined from three different slices (the top, middle
and bottom slices) and then averaged.
Contrast-to-noise ratio (CNR)
The CNR (background Perspex to contrast agents) was selected as
a standardization method to compare the two contrast agents. The region of interest (ROI) in each sample image was drawn around with a
4 mm diameter circle. The mean in pixels of each ROI in each sample
and the mean of the background area of the phantom were calculated.
The CNR is expressed as [43]:
CNR =
ROI m − ROI b
SDb
The ROIm and ROIb represent the CT values of the contrast
material in a ROI of the samples and in the background of phantom,
respectively. SDb represents the standard deviation of the CT number
of the background. CNR values were collected for both contrast
agents at each tube potential and evaluated for differences in the mean
using one tail Student’s t-test (paired), with p=0.05 or less considered
significant.
• Page 2 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
Figure 1: (a) Perspex phantom containing contrast agent solutions, and (b) the phantom positioned at the iso-center of the CT gentry.
Results and Discussion
Synthesis and characterization of PVP coated Bi2S3 NPs
The PVP-coated Bi2S3 NPs were fabricated as previously described
using a two-step process, whereby oleic acid coated Bi2S3 NPs are initially prepared and then coated with PVP [40]. In this instance, the
reaction temperature was reduced to 110°C to facilitate the formation
of slightly larger NPs, to obtain the optimal size for CT attenuation.
Lower temperatures (<110°C) allow larger metallic nanomaterials to
increase in size [37,44]. The optimal NP sizes for CT attenuation have
been reported to be between 4 and 20 nm [45]. Previous studies have
also demonstrated that the NP size can be controlled through variation of the reaction temperature [46,47].
Dynamic light scattering (DLS) analysis revealed that the hydrodynamic diameter of the NPs ranged from 4 to 18 nm (mean 5.8 nm)
(Figure 2). This was also confirmed via transmission electron microscopy (TEM), which provided NPs diameters ranging from 5 to 15 nm
(Figure 3), and revealed that the NPs had a spherical morphology.
X-ray photon spectroscopy (XPS) of the NPs showed two peaks located at 158.5 and 163.5 eV (Figure 4), which can be attributed to the
binding energy of Bi 4f 7/2 and Bi 4f 5/2, respectively, whilst a small
peak at 161.4 eV corresponded to the binding energy of S2p. The XPS
results, as well as the X-ray diffraction (XRD) results (Figure 5) are in
good agreement with previous data on Bi2S3 NPs 37.
CT scannings
The range of tube potentials selected in this study (80 to 140 kV)
represents the range normally used in clinical CT scanners with contrast agents. The X-ray absorption of Bi2S3 NPs was compared to the
clinical iodinated contrast agent Iohexol at various concentrations
and X-ray tube potentials as shown in Figure 6a-d. As expected, CT
numbers (report as Hounsfield units (HU)) increased linearly with increasing concentrations of both Bi2S3 NPs and the iodinated contrast
agent. This was due to the higher atoms density at higher concentrations, which increased the X-ray attenuation value and subsequently
increased the HU density during CT imaging. At all tube potentials
(80 to 140 KVp), the CT numbers (HU) were greater for Bi2S3 NPs
than the iodinated contrast agent at the same concentration, indicating higher absorption -ray, but both displayed the same trend with
respect to tube potential. This was also observed in CT cross-sectional
Volume 6 • Issue 4 • 1000222
slices of Bi2S3 NPs and iodinated contrast agent solutions at concentrations of 65 mM and increasing tube potentials (Figure 7). The regions that contained Bi2S3 NPs had higher attenuation compared to
iodine at all tube potentials, indicating enhanced contrast. This was
likely related to differences in interaction between X-rays and the
two contrast agents. The dominant interaction of X-rays with tissue
and water results from Compton scattering (CS) [48,49]. In contrast,
for high atomic number (Z) elements, PE would be more significant
than for low Z elements as PE depends strongly on a material’s atomic
number (⍺Z3). Therefore, the CT attenuation of high Z elements (I
or Bi) is greater when compared to the attenuation of water (or soft
tissue).
The iodine’s k-edge (33.2 KeV) occurs just below 80 KVp and
the highest attenuation rate for iodine is expected to be at this energy range. The CT attenuation decreases with increasing energy (80
to 140 KVp) due to the reduction of the probability of both PE and CS
since these energies are beyond the K-edge value of I. The difference
in the attenuation number by Bi atoms compared to water molecules
is expected to be larger than iodine and water. This is because the Xray interaction probability with Bi decreases due to the reduction in
PE and CS, whereas in water there is only reduction in CS. However,
across all the range of energies the difference in attenuation between
Bi and water is larger compared to that of I and water. It follows that
the probability of X-ray interaction is highly dependent on physical
density (ρm), electron density (ρe) and atomic number (Z). Thus, it is
logical that Bi2S3 NP displayed much greater attenuation for applications employing tube potentials between 80 to 140 KVp. It was also
noted that Bi2S3 NPs exhibited stronger attenuation in CT imaging
at 80 KVp than at other potentials. However, between 100 and 140
KVp, the attenuation only slightly changed. The cross-sectional CT
images from the contrast phantoms also show similar results, where
the area containing Bi at 80 kV had a higher attenuation value than
at other X-ray tube voltages. This is due to the high probability of interaction with photons (both PE and CS) at 80 KVp, which is lower
at potentials from 100 to 140 KVp. The contrast-to-noise ratio (CNR)
of Bi2S3 NP and iodinated contrast agents was calculated at equivalent
concentrations [26,35,50,51] and 65 mM (Figure 8 a-b). The CNR results are directly dependent on the attenuation number of the contrast
agents. The value of CNR increases with increasing concentrations
of Bi and I within the system, as more atoms are available at higher
• Page 3 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
Figure 2: Size distribution of PVP coated Bi2S3 NPs measured by DLS.
Figure 3: TEM images of PVP coated Bi2S3 NPs showing (a) individual spherical NPs, and (b) aggregates, which may form as a result of the TEM sample preparation.
Figure 4: X-ray photon spectra of PVP coated Bi2S3 NPs.
Volume 6 • Issue 4 • 1000222
• Page 4 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
Figure 5: XRD pattern of PVP coated Bi2S3 NPs.
Figure 6: CT numbers for Bi2S3 NPs and the iodinated contrast agent as a function of concentration at tube potentials of (a) 80, (b) 100, (C) 120 and (d) 140
KVp.
Volume 6 • Issue 4 • 1000222
• Page 5 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
concentrations for interaction. Hence, higher attenuation coefficients
were obtained leading to bigger differences in attenuation between
the solution and the Perspex (container). For the iodinated contrast
agent, the CNR was found to decrease with increasing tube potentials
at all concentrations. A higher image contrast enhancement for the
iodinated contrast agent was observed at a lower tube potential due
to the high attenuation value produced from the effect of its k-edge
(33.2 KeV) at low energies. The CNR results for the iodinated contrast
agent are consistent with previous studies [49,50]. For Bi there was
a slight signal reduction from 80 KVp to 140 KVp. The CNR data
for Bi NPs follows a similar trend to the iodinated contrast agent.
However, at potentials higher than 80 KVp, the Bi NPs CNR showed
a pattern of reduction. This could be due to the photon interaction
(PE and CS) having a much more pronounced impact at 80 KVp and
then decreasing with potentials from 100 to 140 KVp. The effect of
the tube potential on contrast enhancement was validated by calculating the differences in CNR values between contrast agents from
lower to higher tube potentials at a concentration of 65 mM. Comparison of the CNRs of both contrast agents as a function of tube
potentials is represented in Figure 9. At all tube potentials, Bi2S3 NP
exhibited higher CNR values because of the material’s comparatively
high atomic number, physical density and electron density. The difference in contrast enhancement between Bi2S3 NP and iodinated
contrast agents increased with tube potential. At lower KVp, Bi2S3
NP showed a one to two-fold increase in contrast enhancement compared to the iodinated contrast agent. This enhancement difference
continued to increase and was greatest (three to four times) at 140
KVp. These findings of a 4-fold signal enhancement of Bi2S3 NPs over
I at 140 KVp are in close agreement to studies by Rabin et al., where
a 5-fold increase in attention was reported [12]. Theoretical mass attenuation data were obtained using the NIST mass attenuation plots
(Table 1). The mass attenuation coefficient curves of Bi and I were
plotted versus photon energy in Figure 10. The total mass attenuation
coefficients for both I and Bi are a result of the contribution of both
photo-electric and Compton effects. The k-edge value represents an
enhancement level threshold in the attenuation of Bi and I at a particular energy. This increased attenuation occurs at 33.2 KeV for I
and 91 KeV for Bi, due to the binding energy of the k-shell electrons
when the photoelectric absorption occurs. The attenuation data was
selected to match the photon energy in KeV and lies between one
third and one half of the selected tube potential (80 to 160 KVp). The
mass attenuation coefficient decreased for both Bi and I from its highest value at 80 KVp and was reduced at 140 KVp. Interestingly, the
attenuation trend for Bi was observed to sharply increase at 160 KVp.
The calculated CT numbers followed the same trend as the mass attenuation coefficient. There is close agreement between these results
and the calculated theoretical data. The measured mass attenuation
coefficient of both agents was strongest at 80 KVp, and as the X-ray
tube potential increased, the attenuation decreased. Iodine’s K-edge
occurs at photon energy of 33.2 KeV, when the tube potential is about
60 KVp and as that potentials increases, the attenuation gradually deceases. At 80 KVp, iodine’s attenuative properties are maximized but
are not further improved at higher tube potentials. At a high tube
potential (>160 KVp), bismuth’s k-edge optimum occurs at (91 KeV),
where it absorbs a high number of photons. Below this range (80 to
140 KVp), the strongest HU density for Bi occurs at 80 KVp due to
the high number of X-ray photons contributing to the PE and CS and
once more, less contribution occurs at higher potentials.
The results presented in this study clearly demonstrate the potential for Bi-based NP to act as improved contrast agents at clinically
relevant tube potentials when compared to conventional iodinated
contrast agents. A lower concentration of Bi NPs can be also be used
without resulting in viscosity issues [37]. While it is possible to use
higher concentrations of iodinated contrast agents for greater image
enhancement, this also increases the risk of adverse reactions in some
patients [51]. Taking into consideration these factors, Bi2S3 NPs are a
promising potential complement contrast agent at the studied tube
potentials. This is especially relevant for cases where conventional
iodine based contrast media cannot be used due to patient incompatibility (e.g., hypersensitivity reactions). Also importantly, the
nanoparticles have a longer circulation time, thus improving their
value as targeted agents by maintaining a relatively high blood concentration at the targeted tissue.
Conclusion
This phantom study has shown that the inclusion of Bi NPs provides higher contrast efficacy than iodinated contrast agents at tube
potentials of 80 to 140 KVp. These contrast enhancement concen-
Figure 7: Cross sectional CT images of contrast phantoms containing Bi2S3 NP and iodinated contrast agents. Samples were imaged at equimolar concentrations
(65 mM) and tube potentials of 80, 100, 120 and 140 KVp.
Table 1: Mass attenuation coefficients (µ) of measured X-ray energy spectra using published NIST mass attenuation plots. CT valaues for Bi and I were calculated
using published NIST mass attenuation data.
KVp
KeV
µBi
µI
µ water
CT # for Bi (×103)
80
46
88
14
0.24
364
55
100
60
53
8.0
0.21
247
39
120
67
38
5.6
0.20
186
27
140
80
27
3.3
0.18
149
17
160
91
70
2.5
0.17
411
14
Volume 6 • Issue 4 • 1000222
• Page 6 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
tration increases as it is dependent and also depend on the applied
potential to the anode of the x-ray tube, i.e., the average beam energy.
At low energy (80 KVp), Bi NPs display a one to two-fold enhancement in attenuation compared to clinical contrast agents. Increasing
the tube potential to 140 KVp resulted in even further improved attenuation levels, with Bi NPs displaying 3 to 4-fold greater contrast
enhancement over clinical iodinated contrast agents.
This research clearly shows the potential for Bi-based contrast
media as an alternative to conventional iodinated contrast agents,
Figure 10: Mass attenuation coefficient as a function of energy showing the
K-edge values for (a) iodine and (b) bismuth. Theoretical mass attenuation
data were obtained using published NIST mass attenuation plots.
particularly in cases where patients have had adverse reactions to
conventional iodine-based contrast media and when higher contrast
levels are require. As an added advantage, the long vascular half-life of
Bi-based contrast agents further improves their value as a replacement
to iodine in targeted imaging when prolonged circulation times are
necessary.
Figure 8: Calculated contrast-to-noise ratios (CNR) for (a) iodinated and (b)
Bi2S3 NP contrast agents at different concentrations and tube potentials.
References
1. Doi K (2014) Current status and future potential of computer-aided diagnosis
in medical imaging. Br J Radiol 78: s3-s19.
2. Cochard LR (2012) Netter's introduction to imaging. (1st edtn), St. Louis, Mo:
Elsevier, St. Louis, Mo.
3. Yu SB, Watson AD (1999) Metal-Based X-ray Contrast Media. Chem Rev
99: 2353-2378.
4. Lee N, Choi SH, Hyeon T (2013) Nano‐Sized CT Contrast Agents. Adv Mater
25: 2641-2660.
5. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, et al. (2007) Noninvasive
detection of macrophages using a nanoparticulate contrast agent for
computed tomography. Nature medicine 13: 636-641.
6. Liu Y, Ai K, Lu L (2012) Nanoparticulate X-ray Computed Tomography
Contrast Agents: From Design Validation to in Vivo Applications. Acc Chem
Res 45: 1817-1827.
7. Lusic H, Grinstaff MW (2012) X-ray-Computed Tomography Contrast Agents.
Chem rev 113: 1641-1666.
Figure 9: Contrast-to-noise ratios (CNR) obtained from CT images as a
function of the tube voltage for Bi2S3 NP and iodinated contrast agents.
Volume 6 • Issue 4 • 1000222
8. Jost G, Pietsch H, Lengsfeld P, Hütter J, Sieber MA (2010) The Impact of
the Viscosity and Osmolality of Iodine Contrast Agents on Renal Elimination.
Invest Radiol 45: 255-261.
• Page 7 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
9. Singh J, Daftary A (2008) Iodinated contrast media and their adverse
reactions. J Nucl Med Technol 36: 69-74.
10. Morcos S, Thomsen H (2001) Adverse reactions to iodinated contrast media.
European Radiol 11: 1267-1275.
11. Mattrey RF, Aguirre DA (2003) Advances in contrast media research 1. Acad
Radiol 10: 1450-1460.
12. Rabin O, Perez JM, Grimm J, Wojtkiewicz G, Weissleder R (2006) An X-ray
computed tomography imaging agent based on long-circulating bismuth
sulphide nanoparticles. Nat Mat 5: 118-122.
13. Speck U (2008) Contrast agents: X-ray contrast agents and molecular
imaging–a contradiction? In Molecular imaging I, Springer: 167.
14. Hallouard F, Anton N, Choquet P, Constantinesco A, Vandamme T (2010)
Iodinated blood pool contrast media for preclinical X-ray imaging applications-a review. Biomaterials 31: 6249-6268.
15. Zukiwski AA, David CL, Coan J, Wallace S, Gutterman JU, et al. Increased
incidence of hypersensitivity to iodine-containing radiographic contrast media
after interleukin-2 administration. Cancer 65: 1521-1524.
16. Webb JA, Stacul F, Thomsen HS, Morcos SK (2003) Late adverse reactions
to intravascular iodinated contrast media. Eur Radiol 13: 181-184.
17. Fleischmann D (2003) Use of high concentration contrast media: principles
and rationale-vascular district. Eur J Radiol 45: S88-S93.
18. Krause W, Leike J, Schuhmann-Giampieri G, Sachse A, Schmiedl U, et al.
Iopromide-carrying liposomes as a contrast agent for the liver. Acad Radiol
3: S235- S237.
19. Kweon S, Lee HJ, Hyung WJ, Suh J, Lim JS, et al. (2010) Liposomes
coloaded with iopamidol/lipiodol as a RES-targeted contrast agent for
computed tomography imaging. Pharm Res 27: 1408-1415.
20. Rivera EJ, Tran LA, Hernández-Rivera M, Yoon D, Mikos AG, et al. Bismuth@
US-tubes as a potential contrast agent for X-ray imaging applications. J Mater
Chem B 1: 4792-4800.
32. Andrews PC, Ferrero RL, Forsyth CM, Junk PC, Maclellan JG, et al.
(2011) Bismuth(III) Saccharinate and Thiosaccharinate Complexes and the
Effect of Ligand Substitution on Their Activity against Helicobacter pylori.
Organometallics 30: 6283-6291.
33. Gisbert JP (2011) Helicobacter pylori eradication: A new, single-capsule
bismuth-containing quadruple therapy. Nature Reviews Gastroenterology
and Hepatology 8: 307-309.
34. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, et al. (2011)
Helicobacter pylori eradication with a capsule containing bismuth subcitrate
potassium, metronidazole, and tetracycline given with omeprazole versus
clarithromycin-based triple therapy: a randomised, open-label, non-inferiority,
phase 3 trial. The Lancet 377: 905-913.
35. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, et
al. (2010) Sequential cytarabine and alpha-particle immunotherapy with
bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer
Res 16: 5303-5311.
36. Leussink BT, Baelde HJ, Broekhuizen TM, E Heer, Der Voet GB, et al. Renal
epithelial gene expression profile and bismuth-induced resistance against
cisplatin nephrotoxicity. Human Exp Toxicol 22: 535-540.
37. Ai K, Liu Y, Liu J, Yuan Q, He Y, et al. (2011) Large-Scale Synthesis of Bi2S3
Nanodots as a Contrast Agent. Advanced Materials 23: 4886-4892.
38. Brown AL, Naha PC, Benavides V, Litt HI, Goforth AM, et al. (2014) Synthesis,
X-ray Opacity, and Biological Compatibility of Ultra-High Payload Elemental
Bismuth Nanoparticle X-ray Contrast Agents. Chem Mater 26: 2266- 2274.
39. Fang Y, Peng C, Guo R, Zheng L, Qin J, (2013) Dendrimer-stabilized bismuth
sulfide nanoparticles: synthesis, characterization, and potential computed
tomography imaging applications. Analyst 138: 3172-3180.
40. Algethami M, Geso M, Piva T, Blencowe A, Lu L, et al. (2015) Radiation Dose
Enhancement Using Bi2S3 Nanoparticles in Cultured Mouse PC3 Prostate
and B16 Melanoma Cells. NanoWorld Journal 1: 97.
21. Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, et al. (2008)
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano
lett 8: 4593-4596.
41. Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, et al. (2011)
X-ray computed tomography imaging of breast cancer by using targeted
peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed Engl 50:
12308-12311.
22. Wyss C, Schaefer SC, Juillerat-Jeanneret L, Lagopoulos L, Lehr HA, et al.
(2009) Molecular imaging by micro-CT: specific E-selectin imaging. European
radiology 19: 2487-2494.
42. Alqathami M, Blencowe A, Geso M, G. Ibbott (2016) Quantitative 3D
Determination of Radiosensitization by Bismuth-Based Nanoparticles. J
Biomed Nanotechnol12: 464471.
23. Burda C, Xiaobo C, Narayanan R, El-Sayed MA (2005) Chemistry and
Properties of Nanocrystals of Different Shapes. Chem Rev 105: 1025-1102.
43. Funama Y, Awai K, Nakayama Y, Kakei K, Nagasue N, et al. (2005) Radiation
dose reduction without degradation of low-contrast detectability at abdominal
multisection CT with a low-tube voltage technique: Phantom study. Radiology
237: 905-910.
24. Cai QY, Kim SH, Choi KS, Kim SY, Byun SJ, et al. (2007) Colloidal gold
nanoparticles as a blood-pool contrast agent for X-ray computed tomography
in mice. Invest Radiol 42: 797-806.
25. Hainfeld JF, Slatkin DN, Smilowitz HM (2004) The use of gold nanoparticles
to enhance radiotherapy in mice. Physics in Medicine and Biology 49: N309.
26. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM (2006) Gold nanoparticles:
a new X-ray contrast agent. Br J Radiol 79: 248-253.
27. Dykman LA, Khlebtsov N (2011) Gold Nanoparticles in Biology and Medicine:
Recent Advances and Prospects. Acta Naturae 3: 34-55.
28. Albanese A, Tang PS, Chan WC (2012) The effect of nanoparticle size,
shape, and surface chemistry on biological systems. Annu Rev Biomed Eng
14: 1-16.
29. Briand GG, Burford N (1999) Bismuth compounds and preparations with
biological or medicinal relevance. Chem Rev 99: 2601-2658.
30. Larsen A, Martiny N, Stoltenberg M, Danscher G, Rungby J (2003)
Gastrointestinal and systemic uptake of bismuth in mice after oral exposure.
Pharmacol Toxicol 93: 82-90
31. Tillman L, Drake F, Dixon J, Wood J (1996) Safety of bismuth in the treatment
of gastrointestinal diseases. Alimentary Pharmacology & Therapeutics 10:
459-467.
Volume 6 • Issue 4 • 1000222
44. A. Pathak (2013) Aqueous Medium Synthesis Route for Randomly Stacked
Molybdenum Disulfide. Journal of Nanoparticles 671214.
45. C Xu, GA Tung, Sun S (2008) Size and Concentration Effect of Gold
Nanoparticles on X-ray Attenuation As Measured on Computed Tomography.
Chemistry of Materials 20: 4167-4169.
46. Xiliang Q, Yang C, Tiesong L, Peng H, Jun W, et al. (2014) Large-Scale
Synthesis of Silver Nanoparticles by Aqueous Reduction for Low-Temperature
Sintering Bonding. J Nanomaterials 594873.
47. Burda C, Chen X, Narayanan R, El-Sayed MA (2005) Chemistry and
Properties of Nanocrystals of Different Shapes. Chemical reviews 105: 10251102.
48. Murakami Y, Kakeda S, Kamada K, Ohnari N, Nishimura J, et al. (2010)
Effect of Tube Voltage on Image Quality in 64-Section Multidetector 3D CT
Angiography: Evaluation with a Vascular Phantom with Superimposed Bone
Skull Structures. American Journal of Neuroradiology 31: 620-625.
49. Razak HRA, Rahmat SMSS, Saad WMM (2013) Effects of different tube
potentials and iodine concentrations on image enhancement, contrast-tonoise ratio and noise in micro-CT images: a phantom study. Quantitative
imaging in medicine and surgery 3: 256-261.
• Page 8 of 9 •
Citation: Algethami M, Blencowe A, Feltis B, Geso M (2017) Bismuth Sulfide Nanoparticles as a Complement to Traditional Iodinated Contrast Agents at
Various X-Ray Computed Tomography Tube Potentials. J Nanomater Mol Nanotechnol 6:4.
doi: 10.4172/2324-8777.1000222
50. Szucs-Farkas Z, Verdun FR, Allmen G, Mini RL, P Vock (2008) Effect of X-ray
Tube Parameters, Iodine Concentration, and Patient Size on Image Quality
in Pulmonary Computed Tomography Angiography: A Chest-Phantom-Study.
Investigative radiology 43: 374-381.
51. Maddox TG (2002) Adverse reactions to contrast material: Recognition,
prevention, and treatment. American family physician 66: 1229-1234.
Author Affiliation
Top
1
Discipline of Medical Radiations, School of Health and Biomedical sciences,
RMIT University, Melbourne, Victoria 3109, Australia
2
School of Pharmacy and Medical Sciences, University of South Australia,
Adelaide, South Australia 5000, Australia
3
Future Industries Institute, University of South Australia, Mawson Lakes,
South Australia 5095, Australia
4
Discipline of Biomedical Sciences, School of Health and Biomedical sciences,
RMIT University, Melbourne, Victoria 3109, Australia
Submit your next manuscript and get advantages of SciTechnol
submissions
80 Journals
21 Day rapid review process
3000 Editorial team
5 Million readers
More than 5000
Quality and quick review processing through Editorial Manager System
Submit your next manuscript at ● www.scitechnol.com/submission
Volume 6 • Issue 4 • 1000222
• Page 9 of 9 •